RCS - Angle PLC - EACR 2025: Innovation in AR expression profiling

AngleAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250617:nRSQ0769Na&default-theme=true

RNS Number : 0769N  Angle PLC  17 June 2025

 For immediate release  17 June 2025

 

ANGLE plc ("the Company")

 

ANGLE presents new data at EACR 2025 Highlighting Innovation in Androgen
Receptor EXPRESSION profiling

 

Poster presentation highlights development of a novel CTC-based assay

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce the presentation of
a poster at the European Association for Cancer Research (EACR) Congress,
taking place in Lisbon, Portugal from 16-19 June 2025.

 

The poster entitled 'Combined microfluidic isolation and immunofluorescence
staining of circulating tumour cells for the assessment of Androgen Receptor
expression in metastatic prostate cancer blood samples', is being presented
during the Biomarkers in Tissue and Blood session on Tuesday 17 June 2025.

 

This assay addresses a significant unmet need in prostate cancer. The androgen
receptor (AR) plays a central role in driving disease growth and progression,
and changes in AR can lead to resistance to current treatments and the
development of advanced incurable disease known as metastatic
castration-resistant prostate cancer (mCRPC). With at least 130 ongoing
clinical studies and a projected AR inhibitor market value of US $9.8 billion
by 2032, there is growing demand for assays that can monitor AR activity(1).

 

ANGLE has developed a new approach for repeatable assessment of AR expression
in prostate cancer patients using the Parsortix system and ANGLE's AR
immunofluorescence assay. The assay was tested on blood spiked with prostate
cancer cells exposed to increasing AR drug concentrations. The results showed
a clear, statistically significant reduction in AR expression as AR-drug
concentration increased, from over 80% AR-positive cells in untreated samples
to under 20% at the highest drug level. This demonstrates the assay's high
sensitivity and highlights its potential utility for pharmacodynamic
assessment, enabling customers to monitor treatment response in real-time.

 

The assay was then validated in blood samples from 20 patients with mCRPC. 50%
of patients were CTC-positive and all CTC-positive patients had AR-positive
CTCs enabling the assessment of AR expression levels. CTC clusters, which are
known to be up to 100 times more metastatic, were observed in 80% of
CTC-positive patients. All CTCs detected were mesenchymal or undergoing EMT,
highlighting the importance of using the marker-independent Parsortix system
in this patient cohort.

 

This work demonstrates how ANGLE's Portrait AR workflow enables sensitive,
real-time monitoring of AR expression from a simple blood draw. The assay is
now available as part of ANGLE's assay menu to support pharma customers with
longitudinal biomarker assessment in AR-targeted clinical trials.

 

The poster will be available on ANGLE's website from 20:00 on Tuesday 17 June:
https://angleplc.com/resources/posters/
(https://angleplc.com/resources/posters/)

 

ANGLE Chief Scientific Officer, Karen Miller, commented:

"This work underscores the value of ANGLE's Parsortix system for enabling
detailed protein analysis directly in intact CTCs. The androgen receptor assay
development programme has successfully been completed, and we are excited by
its potential to repeatably monitor drug response and resistance in prostate
cancer trials. Sharing this data at EACR reflects our ongoing commitment to
advancing precision oncology with innovative, real-world solutions."

 

1.   https://dataintelo.com/report/androgen-receptor-ar-inhibitor-market
(https://dataintelo.com/report/androgen-receptor-ar-inhibitor-market)

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer.  The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood.  The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays.  The end
user is responsible for the validation of any downstream assay.  The
standalone device, as indicated, does not identify, enumerate or characterize
CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs,
including monitoring indications or as an aid in any disease management and/or
treatment decisions.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFZGMVLVMGKZM